FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896462956> ?p ?o ?g. }

• W2896462956 endingPage "S166" @default.
• W2896462956 startingPage "S165" @default.
• W2896462956 abstract "To evaluate local control outcomes of liver metastases treated with proton stereotactic body radiation therapy (SBRT). Secondary objectives include evaluation of toxicity. Patients diagnosed with metastatic disease to the liver treated with proton SBRT between 2012-2017 per NRG-BR001 study of SBRT for the treatment of multiple metastases were included. Tumor motion was accounted for using either respiratory management or 4D CT scan. Important aspects of plan assessment included dose restricting when close to bowel and keeping V15 (volume of liver receiving at least 15 Gy) or V21 less than 700cc's of normal liver in 3 or 5 fraction plans respectively. In-field local control was evaluated according to RECIST 1.1 criterion. Radiation induced liver disease was evaluated using CTCAE 5.0 criteria. A total of 41 patients with 80 lesions were included in this analysis with a median age of 65.5 years (range 33-87). Dose/fractionation included 50Gy / 5 fractions (19%), 30Gy / 5 fractions (16%), and 30Gy / 3 fractions (16%). The primary cancer site was 51% colorectal, 17% breast, and 33% other. The mean number of metastases treated was 1.7 (range 1-5) with mean tumor diameter of 2.7 cm ± 1.6 cm (range 0.7 – 7.3). With a mean follow up of 14.5 months (range 1 – 44), local control at 6 months and 1 year was 92% and 75%, respectively. No radiation induced liver disease was detected. Grade 1 and grade 2 toxicities were 38% and 6% respectively. No patient developed grade 3 or higher toxicity. Predicted liver toxicity was minimal, with median V15 of 205cc (interquartile range; IQR 137-235) and median V21 of 155cc (IQR 64 – 236) for 3 and 5 fraction plans respectively. Proton SBRT for liver metastases demonstrated a high rate of local tumor control with minimal toxicity. The integral dose advantage allows patients to have multiple courses of full dose therapy while still maintaining liver dose constraints. This is especially important, as out of field liver metastases are one of the most common sites of recurrence or progression in these patients." @default.
• W2896462956 created "2018-10-26" @default.
• W2896462956 creator A5000113257 @default.
• W2896462956 creator A5001344640 @default.
• W2896462956 creator A5005427020 @default.
• W2896462956 creator A5031366321 @default.
• W2896462956 creator A5034369890 @default.
• W2896462956 creator A5050866892 @default.
• W2896462956 creator A5063497604 @default.
• W2896462956 creator A5087757881 @default.
• W2896462956 date "2018-11-01" @default.
• W2896462956 modified "2023-09-25" @default.
• W2896462956 title "Proton SBRT for Liver Metastases - Results of 5-year Experience for 80 Hepatic Lesions Based on NRG-BR001" @default.
• W2896462956 doi "https://doi.org/10.1016/j.ijrobp.2018.07.024" @default.
• W2896462956 hasPublicationYear "2018" @default.
• W2896462956 type Work @default.
• W2896462956 sameAs 2896462956 @default.
• W2896462956 citedByCount "1" @default.
• W2896462956 countsByYear W28964629562019 @default.
• W2896462956 crossrefType "journal-article" @default.
• W2896462956 hasAuthorship W2896462956A5000113257 @default.
• W2896462956 hasAuthorship W2896462956A5001344640 @default.
• W2896462956 hasAuthorship W2896462956A5005427020 @default.
• W2896462956 hasAuthorship W2896462956A5031366321 @default.
• W2896462956 hasAuthorship W2896462956A5034369890 @default.
• W2896462956 hasAuthorship W2896462956A5050866892 @default.
• W2896462956 hasAuthorship W2896462956A5063497604 @default.
• W2896462956 hasAuthorship W2896462956A5087757881 @default.
• W2896462956 hasConcept C121608353 @default.
• W2896462956 hasConcept C126322002 @default.
• W2896462956 hasConcept C126838900 @default.
• W2896462956 hasConcept C155806632 @default.
• W2896462956 hasConcept C2779244869 @default.
• W2896462956 hasConcept C2780387249 @default.
• W2896462956 hasConcept C2989005 @default.
• W2896462956 hasConcept C509974204 @default.
• W2896462956 hasConcept C526805850 @default.
• W2896462956 hasConcept C71924100 @default.
• W2896462956 hasConceptScore W2896462956C121608353 @default.
• W2896462956 hasConceptScore W2896462956C126322002 @default.
• W2896462956 hasConceptScore W2896462956C126838900 @default.
• W2896462956 hasConceptScore W2896462956C155806632 @default.
• W2896462956 hasConceptScore W2896462956C2779244869 @default.
• W2896462956 hasConceptScore W2896462956C2780387249 @default.
• W2896462956 hasConceptScore W2896462956C2989005 @default.
• W2896462956 hasConceptScore W2896462956C509974204 @default.
• W2896462956 hasConceptScore W2896462956C526805850 @default.
• W2896462956 hasConceptScore W2896462956C71924100 @default.
• W2896462956 hasIssue "3" @default.
• W2896462956 hasLocation W28964629561 @default.
• W2896462956 hasOpenAccess W2896462956 @default.
• W2896462956 hasPrimaryLocation W28964629561 @default.
• W2896462956 hasRelatedWork W1980770552 @default.
• W2896462956 hasRelatedWork W2040234847 @default.
• W2896462956 hasRelatedWork W2071090381 @default.
• W2896462956 hasRelatedWork W2156028401 @default.
• W2896462956 hasRelatedWork W2167960661 @default.
• W2896462956 hasRelatedWork W2172092959 @default.
• W2896462956 hasRelatedWork W2900343598 @default.
• W2896462956 hasRelatedWork W2978475839 @default.
• W2896462956 hasRelatedWork W4280521662 @default.
• W2896462956 hasRelatedWork W935391112 @default.
• W2896462956 hasVolume "102" @default.
• W2896462956 isParatext "false" @default.
• W2896462956 isRetracted "false" @default.
• W2896462956 magId "2896462956" @default.
• W2896462956 workType "article" @default.